Pharmacovigilance Conferences | Drug Safety Conferences | Europe | USA | Asia Pacific | 2016| Middle East Events

Theme: Ensuring Safer Therapeutics in Healthcare System

Pharmacovigilance 2016

Scientific Program

Renowned Speakers

Brian Edwards
NDA Regulatory Science LTD
UK

Chrissy Cochran
USFDA
USA

Eugenia Hong
The Royal Melbourne Hospital
Australia

Alexey Skripkin
Russian
Federation

Saad Shakir
Drug Safety Research Unit
UK

Cristina Damatarca MD
Agility Clinical
USA

Nathan Cummins MD
Mayo Clinic
USA

Baldo Paolo
National Cancer Institute
Italy

Pharmacovigilance 2016

ConferenceSeries solicts your gracious presence at the upcoming 7^thInternational Conference and Exhibition on Pharmacovigilance scheduled to happen during August 22-24, 2016 in Vienna, Austria focussing on the advancements in pharmacovigilance, clinical trials and risk management.

Join Hands with Global Influencers and Experts from USA (America), Europe, Middle East , Asia Pacific and Africa at Pharmacovigilance Conferences and Drug Safety Conferences happening from August 22-24, 2016 Vienna, Austria

The field of Pharmacovigilance is growing rapidly and its development is making tremendous impacts in medical sciences and pharmaceuticals. 7^th International Conference and Exhibition on Pharmacovigilance emphasizes on how the importance and significance can be gauged by the fact that it has made huge advancements over the course of time and is continuing to influence various sectors. Main theme of 7^th International Conference and Exhibition on Pharmacovigilance is “Ensuring Safer Therapeutics in Healthcare System”.

Track 1: Pre-Clinical and Clinical Trials:

Preclinicâ€‹al trials involves the assessment of of potential therapeutic interventions in cells and animals. Clinical trials is the research conducted on patients using of patient data, disease mechanisms, therapeutic interventions and epidemiology. Clinical data is a key feature transforming basic research into medical care. Pre-Clinical and Clinical Trials involve human subjects to intervention to study the cause-and-effect relationship between a medical intervention and a health outcome. The perfect outcome of clinical trials is minimize risks, enhance benefits, and optimal use of an intervention of therapeutic drugs.

9th World Drug Delivery Summit, June 30-July 02, 2016 New Orleans, Louisiana, USA; Drug Formulation & Bioavailability Congress, September 05-07, 2016 Beijing, China; 2nd International Conference on Therapeutic Drug Monitoring and Toxicogenomics, August 25-26, 2016 Philadelphia, Pennsylvania, USA; International Conference on Anatomy and Physiology, August 11-13, 2016, Birmingham, UK; 2^nd International Conference and Expo on Drug Discovery & Designing, November 08-09, 2016, Istanbul, Turkey; Outsourcing in Clinical Trials Europe 2016; 5^th Annual Clinical Development and Trials Asia Congress; Outsourcing in Clinical Trials East Coast 2016; European Association of Employed Community Pharmacists in Europe (EPhEU), Association of Pharmacy Professionals (APP), Pharmaceutical Society Of New Zealand (PSNZ), Pharmaceutical Association of Mauritius(PAM).

Track 2 : Adverse Drug Reactions:

Adverse Drug Reaction (ADR) is the contrary reactions caused by taking a medication. Many Adverse Drug Reactions represent an overwhelming side effects of the drug's therapeutic effects. Adverse Drug Reactions of Drugs can be studied by reporting the mechanism of adverse drug reactions and maintaining the drug safety systems. This track is about expected and un-expected drug reactions and its reporting. Manufacturers, Professionals, and Consumers can report Post marketing reports on adverse effects.

2^nd International Conference on Clinical Trials, August 22-24, 2016, Philadelphia, USA; 6^th International Conference and Exhibition on Pharmaceutical Regulatory Affairs and IPR, September 29-Oct 01, 2016, San Atonio, USA; 2nd International Conference on Therapeutic Drug Monitoring and Toxicogenomics, August 25-26, 2016 Philadelphia, Pennsylvania, USA; 2^nd International Conference and Expo on Drug Discovery & Designing, November 08-09, 2016, Istanbul, Turkey; Drug Formulation & Bioavailability Congress, September 05-07, 2016 Beijing, China; 6^th Annual Pharmacovigilance and Risk Management Strategies Forum; Pharmacovigilance and Risk Management Strategies 2016; Conference on Pharmacovigilance and Clinical Trials; Conference on Pharmacovigilance and Drug Safety. European Association of Employed Community Pharmacists in Europe (EPhEU), Pharmaceutical Association of Mauritius(PAM), International Pharmaceutical Federation (FIP), European Pharmaceutical Union (EPU), Pharmaceutical Group of the European Union (PGEU )

Track 3 : Clinical Trials on Various Disorders:

Clinical Trials on various diseases include Clinical Trials in long chronic diseases like AIDS, Benign and Malignant Tumours,Cardiovascular diseases, Diabetes, Clinical Trials on Monoclonal and Polyclonal Antibodies, Neurological, Physiological and Psychological Disorders,

Track 4: Clinical Trials on Various Disorders:

Pharmacovigilance and Risk Management ia set of pharmacovigilance activities and interventions designed to identify, characterise, prevent or minimise risks relating to medicinal and therapeutic products including the assessment of the effectiveness of their clinical interventions.and combination therapies. Drug industry need to promote companies in pharmacovigilance practice to use information technology and to Review softwares used in pharmacovigilance and clinical trials. Monitoring unlicensed, off labels and orphan drugs is major task in risk management. Many experts from different pharmacovigilance CRO's , pharmacovigilance service providers and industrial delegates are participating in this conference to share their knowledge and discuss about the new updates.

3rd International Conference and Exhibition on Advances in HPLC & Chromatography Techniques, March 20-21, 2017 Kuala Lumpur, Malaysia; Drug Formulation & Bioavailability Congress, September 05-07, 2016 Beijing, China; 2nd International Conference on Therapeutic Drug Monitoring and Toxicogenomics, August 25-26, 2016 Philadelphia, Pennsylvania, USA; 6^th International Conference and Exhibition on Pharmaceutical Regulatory Affairs and IPR, September 29-Oct 01, 2016, San Atonio, USA; 2^nd International Conference and Expo on Drug Discovery & Designing, November 08-09, 2016, Istanbul, Turkey; 6^thAnnual Pharmacovigilance and Risk Management Strategies Forum; SCT 37^th Annual Meeting (2016); Conference on Pharmacology and Toxicology Research; Pharmacovigilance and Risk Management Strategies 2016. European Association of Employed Community Pharmacists in Europe (EPhEU), Association of Pharmacy Professionals (APP), Pharmaceutical Society Of New Zealand (PSNZ), Pharmaceutical Association of Mauritius(PAM).

Track 5: Drug Safety

Drug Safety is the pharmacological science ensuring safety and related to the collection, detection, assessment, monitoring, and prevention of adverse side effects with pharmaceutical products. In this track,we discuss Drug safety and its applications in various fields such as Softwares, Training etc.

4th International Conference on Clinical Pharmacy Nov 07-09, 2016 Las Vegas, Nevada, USA; Drug Formulation & Bioavailability Congress, September 05-07, 2016 Beijing, China; 2nd International Conference on Therapeutic Drug Monitoring and Toxicogenomics, August 25-26, 2016 Philadelphia, Pennsylvania; 6^th International Conference and Exhibition on Pharmaceutical Regulatory Affairs and IPR, September 29-Oct 01, 2016, San Atonio, USA; ;6^th Annual Pharmacovigilance and Risk Management Strategies Forum; Pharmacovigilance and Risk Management Strategies 2016; Conference on Pharmacovigilance and Clinical Trials; Conference on Pharmacovigilance and Drug Safety. European Association of Employed Community Pharmacists in Europe (EPhEU),Association of Pharmacy Professionals (APP), Pharmaceutical Society Of New Zealand (PSNZ), Pharmaceutical Association of Mauritius(PAM).

Track 6: Good Pharmacovigilance Practice:

The role of Good Pharmacovigilance Practice and Pharmacoepidemiology in Risk Management is mainly to increase the probability of beneficial effects of a drug in a population than the probability of adverse effects and to maintain the Good Reporting Practices by avoiding the major problems in risk management. Also it is important to concentrate on Signal investigation by gathering the information on new or unknown drug effects that is potentially caused by a medicine and that finally should lead to ensuring safety. The pharmacovigilance and clinical trials services providing companies should have the Pharmacovigilance certification .

Drug Formulation & Bioavailability Congress, September 05-07, 2016 Beijing, China; 2nd International Conference on Therapeutic Drug Monitoring and Toxicogenomics, August 25-26, 2016 Philadelphia, Pennsylvania, USA; 6^th International Conference and Exhibition on Pharmaceutical Regulatory Affairs and IPR, September 29-Oct 01, 2016, San Atonio, USA; 2^nd International Conference and Expo on Drug Discovery & Designing, November 08-09, 2016, Istanbul, Turkey; 6^thAnnual Pharmacovigilance and Risk Management Strategies Forum; SCT 37^th Annual Meeting (2016); Conference on Pharmacology and Toxicology Research; Pharmacovigilance and Risk Management Strategies 2016. European Association of Employed Community Pharmacists in Europe (EPhEU), Association of Pharmacy Professionals (APP), Pharmaceutical Society Of New Zealand (PSNZ), Pharmaceutical Association of Mauritius(PAM).

Track 7: Data Quality Management and Analysis

Good data quality management in pharmacovigilance can be relied only on information gathered from the collection of individual case safety reports and other pharmacoepidemiological data. Quality management consists of quality planning, quality control, quality assurance and quality improvements. The pharmacovigilance data processing cycle starts with data collection and, in computerised systems, data entry; the next step is data storage and maintenance; followed by data selection, retrieval and manipulation. The resulting data output is analysed and assessed. Finally, conclusions are drawn and decisions made. The quality of a pharmacovigilance data system can be defined as a measure of excellence or a state of being free from defects, deficiencies and significant variations and the data quality management includes all the activities that organizations use to direct, control and coordinate the quality of data.

Related Pharmacovigilance Conferences | Drug Safety Conferences | ConferenceSeries Ltd :

4th International Conference on Clinical Pharmacy Nov 07-09, 2016 Las Vegas, Nevada, USA; Drug Formulation & Bioavailability Congress, September 05-07, 2016 Beijing, China; 2nd International Conference on Therapeutic Drug Monitoring and Toxicogenomics, August 25-26, 2016 Philadelphia, Pennsylvania; 6^th International Conference and Exhibition on Pharmaceutical Regulatory Affairs and IPR, September 29-Oct 01, 2016, San Atonio, USA; ;6^th Annual Pharmacovigilance and Risk Management Strategies Forum; Pharmacovigilance and Risk Management Strategies 2016; Conference on Pharmacovigilance and Clinical Trials; Conference on Pharmacovigilance and Drug Safety.European Association of Employed Community Pharmacists in Europe (EPhEU), Association of Pharmacy Professionals (APP), Pharmaceutical Society Of New Zealand (PSNZ), Pharmaceutical Association of Mauritius(PAM).

Track 8: Pharmacovigilance Significance & Scope:

Concept of Pharmacovigilance and its Significance enhances the impact of pharmacovigilance on patient welfare and public health and to know what is pharmacovigilance. This track gives a brief discussion on Pharmacovigilance role in healthcare system. Pharmacovigilance legislation gives an outlook on the rules and laws to follow in Pharmacovigilance practice. The Role of pharma industries in the improvement of pharmacovigilance system is very crucial to maintain the safety data, Detection and Evaluation of drug safety signals through manual and medical devices reporting. Pharmacovigilance scope also deals as Ecopharmacovigilance (EPV), pharmacoenvironmentology and pharmacovigilance in herbal medicines.

4th International Conference on Clinical Pharmacy Nov 07-09, 2016 Las Vegas, Nevada, USA; Drug Formulation & Bioavailability Congress, September 05-07, 2016 Beijing, China; 2nd International Conference on Therapeutic Drug Monitoring and Toxicogenomics, August 25-26, 2016 Philadelphia, Pennsylvania; 6^th International Conference and Exhibition on Pharmaceutical Regulatory Affairs and IPR, September 29-Oct 01, 2016, San Atonio, USA; ;6^th Annual Pharmacovigilance and Risk Management Strategies Forum; Pharmacovigilance and Risk Management Strategies 2016; Conference on Pharmacovigilance and Clinical Trials; Conference on Pharmacovigilance and Drug Safety.European Association of Employed Community Pharmacists in Europe (EPhEU), Association of Pharmacy Professionals (APP), Pharmaceutical Society Of New Zealand (PSNZ), Pharmaceutical Association of Mauritius(PAM).

Track 9 : Diversity in Industrial Clinical Trials and Clinical Research

The clinical trial industry is constantly evolving with diversified clinical research technologies and new clinical studies are being launched at an ever-growing pace. Clinical trials have always been a vital part of the medicine development process, as they provide clinical data on the best ways for treating pathological disorders and diseases. The importance of diversity in industrial clinical trials and clinical research is to ensure that industrial clinical trials are doing due diligence and being as strategic as possible in their results.This diversity makes us to better understand the unmet medical needs of patients.

Related Pharmacovigilance Conferences | Drug Safety Conferences | ConferenceSeries Ltd :

Track 10: Clinical Research and Statistics:

In Clinical Research, Statistics plays a prominent role in regulatory submissions. Statistical analysis of Pharmacovigilance can be achieved by several guidelines mainly ICH guidelines. Adverse Drug Reactions reports can also be considered for the regulatory submission.

2^nd International Conference on Clinical Trials, August 22-24, 2016, Philadelphia, USA; 6^th International Conference and Exhibition on Pharmaceutical Regulatory Affairs and IPR, September 29-Oct 01, 2016, San Atonio, USA, 2nd International Conference on Therapeutic Drug Monitoring and Toxicogenomics, August 25-26, 2016 Philadelphia, Pennsylvania, USA; International Conference on Scientific and Medical Writing November 17-18, 2016 Dubai, UAE; 6^th International Conference and Exhibition on Pharmaceutical Regulatory Affairs and IPR, September 29-Oct 01, 2016, San Atonio, USA; International Conference on Precision Medicine, November 03-05, 2016, Baltimore, USA; Conference on Pharmacodynamics, Biomarkers and Personalised Therapy;Conference on Drug Formulation, Bioavailability and Pharmacological Sciences;6^th Annual Pharmacovigilance and Risk Management Strategies Forum; Pharmacovigilance and Risk Management Strategies 2016; Conference on Pharmacovigilance and Clinical Trials;European Association of Employed Community Pharmacists in Europe (EPhEU), Association of Pharmacy Professionals (APP), Pharmaceutical Society Of New Zealand (PSNZ), Pharmaceutical Association of Mauritius(PAM).

Track 11: Case Report in Clinical Trials:

Case Report in Clinical Trials plays a key role in Clinical Research. Case reports may be on unexpected association between diseases, disorders or symptoms. An unexpected event in the course of observing, treating a patient,possibilities of pathogenesis of a disease or an adverse effect.Unique or rare salient features of a disease or therapeutic approaches or a notable variation of the anatomical structures.

2^nd International Conference on Clinical Trials, August 22-24, 2016, Philadelphia, USA; 6^th International Conference and Exhibition on Pharmaceutical Regulatory Affairs and IPR, September 29-Oct 01, 2016, San Atonio, USA, 2nd International Conference on Therapeutic Drug Monitoring and Toxicogenomics, August 25-26, 2016 Philadelphia, Pennsylvania, USA; 6^th International Conference and Exhibition on Pharmaceutical Regulatory Affairs and IPR, September 29-Oct 01, 2016, San Atonio, USA; International Conference on Precision Medicine, November 03-05, 2016, Baltimore, USA; Conference on Pharmacodynamics, Biomarkers and Personalised Therapy;Conference on Drug Formulation, Bioavailability and Pharmacological Sciences; 6^th Annual Pharmacovigilance and Risk Management Strategies Forum; Pharmacovigilance and Risk Management Strategies 2016; Conference on Pharmacovigilance and Clinical Trials; . European Association of Employed Community Pharmacists in Europe (EPhEU), Association of Pharmacy Professionals (APP), Pharmaceutical Society Of New Zealand (PSNZ), Pharmaceutical Association of Mauritius(PAM).

Track 12: Pharmacokinetics and Pharmacodynamics:

Drugs may undergo, Pharmacokinetics and Pharmacodynamics and toxicity testing through animal testing. The phenomena of drug absorption, distribution, metabolism, and excretion and pharmacokinetic principles enhances the safety and efficacy of therapeutic management of pharmaceutical drugs in an individual patient drug therapy. Pharmacodynamic Interactions, Drug and substance abuse, Drug-drug interactions and clinical drug intervention data allows research scientist estimate a safe starting dose of the drug for clinical trials in humans.

Track 13: PV Data Base Management:

There is an advantage in centralising all safety data, clinical data, analysis and reporting with one provider. Pharmacovigilance Software tool provides comprehensive analysis of adverse events arising from the use of Pharmaceutical products (Medicinal Product, Medical Device, Vaccines, Non-Drug Therapy and Veterinary Medicinal Product). The drug safety database allows the risk- benefit analysis of medicinal products taking into account new and emerging information, in the context of cumulative information. Pharmacovigilance since beginning has been a compliance driven activity, wherein your regulatory compliance determines company’s risk assessment scores. A drug safety database offers scheduling of alerts for expedited cases, follow-up cases and PSUR/PADER reports submission to meet regulatory timeline compliance.

2^nd International Conference on Clinical Trials, August 22-24, 2016, Philadelphia, USA; 6^th International Conference and Exhibition on Pharmaceutical Regulatory Affairs and IPR, September 29-Oct 01, 2016, San Atonio, USA, 2nd International Conference on Therapeutic Drug Monitoring and Toxicogenomics, August 25-26, 2016 Philadelphia, Pennsylvania, USA; 6^th International Conference and Exhibition on Pharmaceutical Regulatory Affairs and IPR, September 29-Oct 01, 2016, San Atonio, USA; International Conference on Precision Medicine, November 03-05, 2016, Baltimore, USA; Conference on Pharmacodynamics, Biomarkers and Personalised Therapy;Conference on Drug Formulation, Bioavailability and Pharmacological Sciences; 6^th Annual Pharmacovigilance and Risk Management Strategies Forum; Pharmacovigilance and Risk Management Strategies 2016; Conference on Pharmacovigilance and Clinical Trials.European Association of Employed Community Pharmacists in Europe (EPhEU), Association of Pharmacy Professionals (APP), Pharmaceutical Society Of New Zealand (PSNZ), Pharmaceutical Association of Mauritius(PAM).

Track 14 : PV Consulting’s and Business opportunity:

Due to the changing resources necessary to fulfil the regulatory requirements, some companies also choose to outsource or out task regulatory affairs to external service providers. Regulatory Affairs department is constantly evolving and growing and is the one which is least impacted during the Acquisition and Merger, and also during recession..The global pharmacovigilance market and Business opportunity bwas valued at USD 2,408.0 million in 2013 and is expected to grow at a CAGR of 12.6% during the forecast period. Phase III clinical trials market was the second largest and was valued at over USD 750.0 million in 2013.

Drug Formulation & Bioavailability Congress, September 05-07, 2016 Beijing, China; 2nd International Conference on Therapeutic Drug Monitoring and Toxicogenomics, August 25-26, 2016 Philadelphia, Pennsylvania, USA; 6^th International Conference and Exhibition on Pharmaceutical Regulatory Affairs and IPR, September 29-Oct 01, 2016, San Atonio, USA; 2^nd International Conference and Expo on Drug Discovery & Designing, November 08-09, 2016, Istanbul, Turkey; 6^thAnnual Pharmacovigilance and Risk Management,Strategies Forum; SCT 37^th Annual Meeting (2016); Conference on Pharmacology and Toxicology Research; Pharmacovigilance and Risk Management Strategies 2016. European Association of Employed Community Pharmacists in Europe (EPhEU), Association of Pharmacy Professionals (APP), Pharmaceutical Society Of New Zealand (PSNZ), Pharmaceutical Association of Mauritius(PAM).

Track 15: Regulatory Affairs:

Regulatory Affairs for clinical trials is the major part in the clinical trials approaches. Every clinical trial must be analysed according to the Regulatory Affairs Guidelines. There are several Regulatory Affairs departments depending upon the countries within evergrowing pace of companies. Global Harmonization in standards has led to consistent approach in regulatory submissions and hence its review.

4th International Conference on Clinical Pharmacy Nov 07-09, 2016 Las Vegas, Nevada, USA; Drug Formulation & Bioavailability Congress, September 05-07, 2016 Beijing, China; 2nd International Conference on Therapeutic Drug Monitoring and Toxicogenomics, August 25-26, 2016 Philadelphia, Pennsylvania, USA; 6^th International Conference and Exhibition on Pharmaceutical Regulatory Affairs and IPR, September 29-Oct 01, 2016, San Atonio, USA; 2^nd International Conference and Expo on Drug Discovery & Designing, November 08-09, 2016, Istanbul, Turkey; 6^thAnnual Pharmacovigilance and Risk Management Strategies Forum; SCT 37^th Annual Meeting (2016); Conference on Pharmacology and Toxicology Research; Pharmacovigilance and Risk Management Strategies 2016. European Association of Employed Community Pharmacists in Europe (EPhEU), Association of Pharmacy Professionals (APP), Pharmaceutical Society Of New Zealand (PSNZ), Pharmaceutical Association of Mauritius(PAM).

Track 16: Growth strategies in Pharma:

Strategies for Growth in Pharma Environment track mainly focused in Strategic development towards FDA approval and Post market product Surveillances. The updates and advances in Pharmacovigilance Regulation system are discussed under Advances in Changing Pharmacovigilance Regulation System track.

Track 17: Pharmacy Practices and its Challenges:

Pharmacy practice is the field of pharmacy which involves developing the professional roles of pharmacists. It includes Disease-state management, Clinical drug interventions, Pharmacy professional development and pharmaceutical care, pharmaceutical compounding and health psychology, patient care, drug abuse prevention, prevention of drug interactions or minimisation of adverse events and drug incompatibility and community pharmacy.

ConferenceSeries is organizing splendorous Pharmaceutical conferences welcomes you to attend the 7^thInternational Conference and Exhibition on Pharmacovigilance to be held during August 22-24, 2016 in Vienna, Austria. It focuses on the advancements in Pharmacovigilance and Risk Management.

The field of Pharmacovigilance is growing rapidly and its development is making tremendous impacts in medical sciences and pharmaceuticals. 7^th International Conference and Exhibition on Pharmacovigilance emphasizes on how the importance and significance can be gauged by the fact that it has made huge advancements over the course of time and is continuing to influence various sectors. Main theme of 7th International Conference and Exhibition on Pharmacovigilance is “Ensuring Safer Therapeutics in Healthcare System”

Why to attend???

With members from around the world focused on learning about Pharmacovigilance and its advances; this is your best opportunity to reach the largest assemblage of participants from the Pharmacovigilance community. Conduct presentations, distribute information, meet with current and potential scientists, make a splash with new drug developments, and receive named recognition at this 3-days event. World-Renowned Speakers, the most recent techniques, developments, and the newest updates in Pharmacovigilance are Hallmarks of this Conference.

Target Audience:

Pharmacovigilance Students, Scientists
Pharmacovigilance Researchers
Pharmacovigilance Faculty
Medical Colleges
Pharmacovigilance Associations and Societies
Business Entrepreneurs
Training Institutes
Software Developing Companies
Manufacturing Medical Devices Companies
Data Management Companies

Summary: Pharmacovigilance 2016 welcomes Attendees, Presenters, and Exhibitors from all over the world to Vienna, Austria. We are delighted to invite you all to attend and register for the “7^th International Conference and Exhibition on Pharmacovigilance” which is going to be held during August 22-24, 2016 at Vienna, Austria. The Organizing Committee is gearing up for an exciting and informative conference program including plenary lectures, symposia, workshops on a variety of topics, poster presentations and various programs for participants from all over the world. We invite you to join us at the Pharmacovigilance 2016, where you will be sure to have a meaningful experience with scholars from around the world. All the members of Pharmacovigilance 2016 Organizing Committee will look forward to meet you at Vienna, Austria.

For more details please visit- http://pharmacovigilance.pharmaceuticalconferences.com/

Importance and Scope: Pharmacovigilance is the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other medicine-related problem. The main purpose of pharmacovigilance is to improve the patient's safety and enhance his care in terms of the use of medicines, including paramedical interventions. Pharmacovigilance also supports public health programs by providing reliable information for the efficient assessment of the risk-benefit profile of medicines, contribute to the assessment of benefits, uses, side effects, harm, effectiveness and risk of medicines, encouraging the safe, rational and more effective (including cost-effective) use of various medicines. Promote education, understanding and clinical training in Pharmacovigilance and its effective availability to the public.

Why Vienna, Austria?

The global market for anti-counterfeiting packaging technologies is expected to increase from nearly $74.2 billion in 2015 to $135.6 billion in 2020, with a compound annual growth rate (CAGR) of 12.8% from 2015 to 2020.

According to the main association of social insurance carriers, the Austrian healthcare and social services sector employed a total of 229,092 people in 2010. Currently there are 266 public and private hospitals incl. specific hospitals, sanatoriums, rehab centers, and care facilities in Austria. The country counts 21.752 physicians, 53.970 nurses, 1.883 medical engineers, and 18.000 established physicians. More than 70 percent of the Austrian popularity have made use of at least one medical service in the recent four weeks. Among these are 81.4 percent of the Austrians who received outpatient care by the OPD “more than 12 months ago or never at all “The million euro expansions and new constructions of hospitals enhance Austria´s hospital quality to a considerable extent. The public expenditure in the healthcare sector amount to more than EUR 150 million per year.

The global pharmacovigilance market is segmented as follows:
Pharmacovigilance Market, by Phases of Drug Development:

Preclinical Studies
Phase I
Phase II
Phase III
Phase IV or Post Marketing Surveillance

Pharmacovigilance Market, by Type of Methods:

Spontaneous Reporting
Intensified ADR Reporting
Targeted Spontaneous Reporting
Cohort Event Monitoring
EHR Mining

Pharmacovigilance Market, by Type of Service:

In-House
Contract Outsourcing

fig1

Conference Highlights

Drug Safety
Adverse Drug Reactions
Pharmacovigilance Significance & Scope
Good Pharmacovigilance Practice
Pharmacovigilance and Risk Management
Pharmacokinetics and Pharmacodynamics
Pre-Clinical and Clinical Trials
Clinical Trials on Various Disorders
Diversity in Industrial Clinical Trials and Clinical Research
Clinical Research and Statistics
Case Report in Clinical Trial
Data Quality Management and Analysis
PV Data Base Managemaent
PV Consultings And Bussiness Opportunity
Regulatory Affairs
Growth Strategies in Pharma
Pharmacy Practices and its Challenges
Entrepreneurs Investment Meet

Global pharmacovigilance market, by clinical trials, 2012 – 2020 (USD Million)

fig2

Welcome Message

Conference Highlights

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date	August 22-24, 2016
Sponsors & Exhibitors	~~Click here for Sponsorship Opportunities~~
Speaker Opportunity Closed	Day 1	Day 2
Poster Opportunity Closed	Click Here to View